Aristotle University Of Thessaloniki (AUTH)
Η επίδοση των υψηλών δόσεων μεθοτρεξάτης στη νεφρική λειτουργία παιδιών με οξεία λεμφοβλαστική λευχαιμία
Abstract
dc:descriptionMTX is a folic acid antimetabolite which is used for decades as an antineoplastic agent. The induction of high dose MTX in many chemotherapeutic protocols of children with ALL has been associated with an important reduction in CNS relapses and an increase of overall survival in those patients. One of the most important side effects of HDMTX is nephrotoxicity, which may be severe or even life-threatening. Tubular obstruction by crystal deposits of MTX and its main metabolite, 7-OH-MTX, is assumed to be the significant mechanism of serious MTX excretion disturbance. Additionally, a disturbance in preglomerular vascular resistance, direct damage to the glomeruli or direct tubular toxicity are considered further nephrotoxic mechanisms. In recent literature, we mainly find only case reports of renal impairment due to HDMTX and there is a lack of many prospective studies related to the incidence of nephrotoxicity of HDMTX in children with ALL. Aim of the present study was to report the incidence and severity of renal dysfunction in children with ALL and to elucidate the pathogenetic mechanisms of glomerular and tubular renal dysfunction. The study was performed between February 2004 and April 2008 in 38 children with ALL, who were hospitalized in the Hematology-Oncology unit of 2nd Pediatric Department of Aristotle University of Thessaloniki and in the Pediatric Oncology unit of Hippokration Hospital of Thessaloniki. All the patients of the study were treated according to the chemotherapeutic protocol ALL BFM-95 and underwent 4 24h sessions of HDMTX with 5 g/m². The average age of the patients was 5,27±2,75 years (range 0,5-12,8 years). 21 of the 38 patients of the study (53%) were boys and 17 (47%) were girls. 32 patients (84,2%) were treated for B-ALL, 4 (10,5%) for T-ALL and 2 of them (5,3%) for diphenotypic ALL. All of our patients were studied at the time of diagnosis (t=0), 24 hours before the 1rst MTX infusion (t=1), 24 hours after the end of the 1rst MTX infusion (t=2), 24 hours after the end of the 2nd MTX infusion (t=3), 24 hours after the end of 3rd infusion (t=4), 24 hours after the end of 4rth infusion (t=5) and after the end of induction phase (t=6). Serum glucose, urea, creatinine, K, Na, Ca, P, and Mg were determined on the reported times for every patient. Additionally, β2-MG, TRP, GFR, and proteinuria were assessed from a 24h urine sample for each patient. Urine pH and α₁-MG were also measured, as well as NAG (a tubular damage marker) before the 1rst and after the 4rth HDMTX session. Finally, serum MTX levels were determined at 24, 42 and 48 hours after each MTX infusion, using fluorescence polarization immunoassay, in 24 out of 38 patients. The results were related to those of 40 age and sex-matched healthy controls. The most important results of our study were the following: in only one out of 152 therapeutic cycles of HDMTX studied (0,66%), there was found an elevation of the plasma creatinine value >1,5 times related to the value before the infusion (an elevation which reflects medium nephrotoxicity grade 2), while borderline reduction of GFR was reported in 3 patients (5 therapeutic cycles). Therapeutic intervention (increasement of diuresis along with increasement of dosage and prolongation of the infusion time of leucovorin) was needed in only one patient of the study. Serum creatinine differed significantly only at t=5 in comparison to control value (p=0,024). GFR was reduced and differed significantly (p<0,01) at t=4 and t=5 from value at diagnosis, at t=3, t=4 and t=5 from value at t=1 and finally at t=3 and t=4 compared to the value at the end of induction therapy. GFR also differed significantly (p<0,01) compared to the values at diagnosis, at the end of infusion therapy and to the values of the control group as well. Urinary α₁-MG and TRP did not differ significantly neither between patients and controls, nor between patients at different times. Patients urinary β₂-MG differed significantly only between t=5 and the end of induction therapy (p=0,02). Patients urinary β₂-MG also differed significantly at t=4 and t=5 (p=0,016 and 0,02 respectively) compared to control values. Urinary NAG at t=5 was increased and differed significantly from value at t=1 (0,019) and values of control group (0,013), although the increased values were borderline. Finally, a negative correlation was found between MTX levels and GFR only at 24 hours after the 4rth infusion (rs= -0,469, p=0,021). Conclusively, nephrotoxocity due to HDMTX in children with ALL is rare. Grade 2 nephrotoxicity presented only 0,66% of our patients, while life-threatening or irreversible renal dysfunction was not reported in our study. In the pathogenesis of nephrotoxocity seem to participate both glomerular and tubular mechanisms, although the changes of tubular function parameters were found to be mild and may reflect primary glomerular disturbancies. The control for absence of preexisting renal dysfunction, the avoidance of using other nephrotoxic factors and the implementation of intensive hydration, along with alkalinization of urine and careful monitoring, are suggested. According to the results of our study, all these measures, could prevent the development of delayed MTX elimination and serious renal dysfunction in children with ALL.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2009
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Theodoridou, Angeliki
- Θεοδωρίδου, Αγγελική
Subjects
dc:subject × 18- Μεθοτρεξάτη
- Υψηλές δόσεις μεθοτρεξάτης
- Νεφρική δυσλειτουργία
- Σπειραματική δυσλειτουργία
- Σωληναριακη δυσλειτουργία
- Οξεία λεμφοβλαστική λευχαιμία
- Νεφροτοξικότητα
- Methotrexate
- High dose methotrexate
- Renal dysfunction
- Glomerular dysfunction
- Tubural dysfunction
- Acute lymphoblastic leukemia
- Nephrotoxicity
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/19509